New heart ablation study targets health disparities in minorities

NCT ID NCT07535268

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a procedure called pulsed field ablation (PFA) to treat atrial fibrillation, a common heart rhythm problem, in patients from racial and ethnic minority groups. About 275 participants will receive the standard PFA treatment using FDA-approved catheters, and researchers will track safety and effectiveness for one year. The goal is to see if this treatment works well in groups that have been underrepresented in past research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FARAWAVE Pulsed Field Ablation Catheter (device)
What this could lead to
If successful, this could show that pulsed field ablation is safe and effective for treating atrial fibrillation in minority populations, helping reduce health disparities.
What could go wrong
This is an observational registry, not a randomized trial, so results may be less definitive. The study is relatively small (275 participants) and only follows patients for one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Mount Sinai Hospital

    RECRUITING

    New York, New York, 10030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Valley Health System

    RECRUITING

    Winchester, Virginia, 22601, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.